Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.86 +8.79%

+$2.32 today

Market cap
$1.86B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.25M

Average 0.34M

COAG Interest Expense

Cost of servicing the company's debt during the period.

Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense of $0 in Q2 FY2026

Q2 FY2026 interest expense was $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How COAG compares with its peers on the latest reported figures

  • COAG's FY2025 interest expense of $0 is the 3rd highest of the 5 companies compared; the peer median is $2.17M.
COAG Competitors Peer median
Interest Expense for COAG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QUREuniQure N.V.LTM Mar 2026$60.92M -2.9%+74.3%336.7%
IRONDisc Medicine, Inc.LTM Sep 2026$4.35M +59.7%——
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$0 ———
DMRADamora Therapeutics, Inc.LTM Mar 2026$0 ———
RLYBRallybio CorporationLTM Mar 2026$0 ——0.0%
Peer median (excluding COAG) $2.17M+28.4%+74.3%168.3%

Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Intrinsic Alpha fair value

Locked

Current Price

$39.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.